Approval · Notice of Compliance 17399 · 2015
KIVEXA: Notice of Compliance 17399
Issued October 2, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17399
- Date
- October 2, 2015
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New pediatric indication for patients less than 18 years f age and weighing less than 25 kg
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KIVEXA | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 300 MG per TAB
- ABACAVIR SULFATE 702 MG per TAB